Inhibikase Therapeutics, Inc. (NasdaqCM: IKT)
Health Care · Biotechnology · US
$2.50
+4.60% today · +35.8% 1Y
Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $435.16M and employs 35 people.
Over the last twelve months the share price has gained 35.8%, trading between 1.33 and 2.53.
Tweenvest scores Inhibikase Therapeutics, Inc. across four factors: quality 33/100. Its strongest factor is quality.
IKT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $435.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.43
- Dividend yield
- —
- Beta (5Y)
- 0.95
- 52-week high
- $2.53
- 52-week low
- $1.33
- Avg volume (3M)
- —
- Shares outstanding
- 182.07M
- Employees
- 35
- Next earnings
- —
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
- ISIN
- US45719W2052
- Founded
- 2008
- Listed since
- Dec 23, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.39 | +0.33% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.95 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.86 | +0.08% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $550.94 | +0.61% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $831.37 | +0.35% |
| argenx SEENXTBR: ARGX | $63.06B | €878.20 | +1.62% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $154.61 | +11.32% |
Figures last refreshed Aug 18, 2026.